| Trial ID: | L1729 |
| Source ID: | NCT00240734
|
| Associated Drug: |
Epoetin Alfa
|
| Title: |
Treatment of Anemia in Diabetic Subjects With CKD
|
| Acronym: |
|
| Status: |
TERMINATED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Anemia
|
| Interventions: |
DRUG: Epoetin alfa
|
| Outcome Measures: |
Primary: The primary endpoint is the hemoglobin response rate, defined as the proportion of subjects who achieve at least a 1 gram per deciliter hemoglobin increase from baseline by Week 17. | Secondary: The secondary endpoints include evaluation of health-related quality life, hemoglobin change over time, time to hemoglobin response, and transfusion utilization.
|
| Sponsor/Collaborators: |
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Collaborators: Ortho Biotech Products, L.P.
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
11
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT
|
| Start Date: |
2005-03
|
| Completion Date: |
2005-09
|
| Results First Posted: |
|
| Last Update Posted: |
2011-06-10
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00240734
|
